1. Rapid Screening of COVID-19 Disease Directly from Clinical Nasopharyngeal Swabs using the MasSpec Pen Technology
- Author
-
Robert Tibshirani, Pedro Henrique Dias Garcia, Alex Ap Rosini Silva, Lisamara Dias de Oliveira Negrini, Rachel J. DeHoog, Danilo Cardoso, Junier Marrero Gutierrez, Sydney C Povilaitis, Kyana Y. Garza, Marcia Ap Antonio, Alena Bensussan, Marcos N. Eberlin, Pedro H Godoy Sanches, Livia S. Eberlin, Sunil Badal, Meredith Spradlin, Andreia M Porcari, Jialing Zhang, Thiago C. Canevari, John Q. Lin, Jonas R Rosa, Alexandre Varao Moura, and Michael F Keating
- Subjects
Moderate to severe ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Disease ,Gold standard (test) ,Asymptomatic ,Rapid detection ,Internal medicine ,Medicine ,medicine.symptom ,business ,Direct analysis - Abstract
The outbreak of COVID-19 has created an unprecedent global crisis. While PCR is the gold standard method for detecting active SARS-CoV-2 infection, alternative high-throughput diagnostic tests are of significant value to meet universal testing demands. Here, we describe a new design of the MasSpec Pen technology integrated to electrospray ionization (ESI) for direct analysis of clinical swabs and investigate its use for COVID-19 screening. The redesigned MasSpec Pen system incorporates a disposable sampling device refined for uniform and efficient analysis of swab tips via liquid extraction directly coupled to a ESI source. Using this system, we analyzed nasopharyngeal swabs from 244 individuals including symptomatic COVID-19 positive, symptomatic negative, and asymptomatic negative individuals, enabling rapid detection of rich lipid profiles. Two statistical classifiers were generated based on the lipid information aquired. Classifier 1 was built to distinguish symptomatic PCR-positive from asymptomatic PCR-negative individuals, yielding cross-validation accuracy of 83.5%, sensitivity of 76.6%, and specificity of 86.6%, and validation set accuracy of 89.6%, sensitivity of 100%, and specificity of 85.3%. Classifier 2 was built to distinguish symptomatic PCR-positive patients from negative individuals including symptomatic PCR-negative patients with moderate to severe symptoms and asymptomatic individuals, yielding a cross-validation accuracy of 78.4% accuracy, specificity of 77.21%, and sensitivity of 81.8%. Collectively, this study suggests that the lipid profiles detected directly from nasopharyngeal swabs using MasSpec Pen-ESI MS allows fast (under a minute) screening of COVID-19 disease using minimal operating steps and no specialized reagents, thus representing a promising alternative high-throughput method for screening of COVID-19.
- Published
- 2021
- Full Text
- View/download PDF